Vivo Bio Tech growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr
Revenue+4.0%
EBITDA−1.4%
Net Income+200.4%
EPS (adj.)+200.4%
Total Assets+4.8%
Total Equity+43.8%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

VIVOBIOT₹13.98

Vivo Bio Tech Limited

· Pharma & Health
₹ CroreMcap ₹21.4 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
Revenue+4.0
EBITDA-1.4
Net Income+200.4
EPS (adj.)+200.4
Total Assets+4.8
Total Equity+43.8
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY25 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.